Protected succinates for enhancing mitochondrial ATP-production

Inventors: Hans Georg Fliri (Ongar, GB); Rhonan Lee Ford (Ongar, GB); David Arthur Scowen (Ongar, GB); Derek Gregory Batcheller (Lund, SE); Kari Henrik Johannes Ehinger (Lund, SE); Mats Eskil Elmer (Lund, SE); Magnus Joakim Hansson (Lund, SE); Karl Fredrik Lennart Sjovall (Lund, SE)

Assignee: NEUROVIVE PHARMACEUTICALS AB

C07D317/34 C07C69/40 C07C69/708 C07C235/06 C07D323/00

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,670,175
App. No.: 14/433,558
Granted: Jun 6, 2017
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R 1 is H or an optionally substituted alkyl group or a group of formula (II) and R 2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.

Claims (2)

1. A protected succinate selected from

2. A composition comprising a protected succinate according to claim 1 and a pharmaceutically or cosmetically acceptable excipient.

Assignments (5)

CHANGE OF NAME Recorded Oct 22, 2020

From: NEUROVIVE PHARMACEUTICAL AB

To: ABLIVA AB

Reel/Frame 054175/0790 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016

From: MITOPHARM LTD.

To: NEUROVIVE PHARMACEUTICALS AB

Reel/Frame 039740/0760 →